Skip to main content

Compugen Licenses Gencarta Database to Japanese Pharma Kyowa-Hakko

NEW YORK, July 17 – Compugen licensed its Gencarta database of annotated genomic, transcription, and proteomic data to the Japanese pharmaceutical company Kyowa-Hakko Kogyo, the companies announced Tuesday.

Financial details of the deal were not disclosed.

“We chose Compugen’s Gencarta database and mining tools because of its exceptional transcriptome analysis,” Seiga Itoh, senior executive officer, drug discovery division of Tokyo-based Kyowa-Hakko said in a statement. “We expect that the integration of Compugen's proprietary and comprehensive gene and protein database into our research will significantly advance our drug discovery and development processes.”

Compugen released Gencarta in March. The database uses Compugen’s Leads algorithm to provide annotation of the transcription factors that bridge genes and proteins. Leads takes into account alternative splicing, in which exons, or coding regions, on one gene can combine in different ways to form different proteins.

Avalon Pharmaceuticals of Gaithersburg, MD, licensed Gencarta in April.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.